Inhibitor Therapeutics, Inc. (INTI) Form 10-Q — Aug 14, 2026
Inhibitor Therapeutics reported a Q2 2026 net loss of $613,933 and disclosed substantial doubt about its ability to continue as a going concern, with cash falling to $515,758 from $2.4 million at year-end against a $1.9 million six-month operating cash burn. The stockholders' deficit deepened to $2.56 million and management is evaluating financing strategies including equity or debt sales, loans, collaborations or licensing. On the regulatory front, the FDA declined the company's previously proposed per-lesion response rate endpoint in May 2026 written responses and recommended a prospective randomized, placebo-controlled trial.
Key figures
- Eps
- -0.01 (six months ended June 30, 2026); -0.00 (Q2 2026)
- Revenue
- 0
- Total Assets
- 637190
- Cash Position
- 515758
- Shares Outstanding
- 173791968
- Warrant exercise price
- 0.35
- G and a six months 2026
- 750103
- R and d six months 2026
- 564126
- Default judgment awarded
- $3.0 million plus attorney's fees and interest
- Deferred revenue mayne pharma
- 3000000
- Spa gross proceeds not received
- $3.0 million
- Itz101 75mg auc ratio vs tolsura
- 105.36%
- Itz101 75mg cmax ratio vs tolsura
- 102.19%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.